FDA Commissioner Scott Gottlieb has taken to Twitter to say that due to the partial shutdown, the FDA cannot accept new 2019 user fees.
FDA Commissioner Scott Gottlieb has taken to Twitter again to state the FDA “continues to be concerned about branded companies creating confusion about the safety and effectiveness of biosimilars and we'll take action if we determine a company is deliberately misleading the public about the safety of these important products.”
A global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes is available to the public. The BRCA Exchange was created through the BRCA Challenge, a long-term demonstration project initiated by the Global Alliance for Genomics and Health to enhance sharing of BRCA1 and BRCA2 data.
The American Society of Clinical Oncology has published standards on the safe handling of hazardous drugs.
A research team led by investigators from the NIH and Global Good has developed a computer algorithm that can analyze digital images of a woman's cervix and accurately identify precancerous changes that require medical attention. This artificial intelligence approach, called automated visual evaluation, has the potential to revolutionize cervical cancer screening, particularly in low-resource settings.
UroGen Pharma Ltd. announced topline results from the ongoing pivotal phase III OLYMPUS clinical trial of UGN-101 (mitomycin gel) for instillation, an investigational mitomycin formulation for the non-surgical treatment of low-grade upper tract urothelial cancer.
A steady, 25-year decline has resulted in a 27% drop in the overall cancer death rate in the United States, translating to approximately 2.6 million fewer cancer deaths between 1991 and 2016. The data come from Cancer Statistics, 2019, the American Cancer Society's widely-quoted annual report on cancer rates and trends.
The Department of Defense Breast Cancer Research Program has published information to allow investigators time to plan and develop applications.
José Baselga was appointed to a key role in driving scientific innovation in oncology at AstraZeneca, the company said.
Cindy Perettie was named CEO of Foundation Medicine Inc. effective Feb. 4.
